Compare National Beverage Corp. (FIZZ) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs Summit Therapeutics Inc — how do they compare? National Beverage Corp. trades at $30.52 (market cap $2.89B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 4.7× National Beverage Corp.'s market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold National Beverage Corp. for 33 Days and Summit Therapeutics Inc for 16 Days on average.
| FIZZ | SMMT | |
|---|---|---|
Market Cap | $2.89B | $13.71B |
Volume | 553,950 | 6,173,057 |
Sector | Consumer Staples | Health |
52-Week High | $37.73 | $26.38 |
52-Week Low | $29.20 | $12.43 |
Typical Hold Time | 33 Days | 16 Days |
Enterprise Value | $2.84B | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
National Beverage Corp. (FIZZ) trades at $30.84, up 4.19% today, showing resilience despite recent earnings misses. The stock exhibits a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, the company maintains strong profitability with 36.21% gross margins and 40.13% ROE, though revenue growth has stalled at $1.2B annually. Recent news highlights margin pressure from input costs and a $3.25 special dividend payment.
FIZZ faces headwinds from three consecutive quarterly earnings misses and declining analyst sentiment with 50% sell ratings. However, strong cash flow generation and high profitability metrics provide support. The key risk remains stagnant revenue growth amid competitive pressures, while the special dividend signals management confidence in financial stability.
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported no revenue in 2025 and a net loss of $1.08 billion, but recent news of a $2 billion strategic investment from AstraZeneca and clinical collaborations has driven significant positive sentiment. Analyst consensus is strongly bullish with a $29.33 price target, reflecting optimism around its cancer drug pipeline.
The outlook hinges on successful clinical trials for ivonescimab, with potential upside from partnership milestones. Key risks include high cash burn, reliance on pipeline success, and competitive pressures. Investors should weigh the speculative nature of biotech investing against the substantial institutional backing and analyst confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
